Stockscreener 앱 받기
3.2213
8.38%
-0.2987
전일 마감가:
$3.52
열려 있는:
$3.56
하루 거래량:
4.26M
Relative Volume:
0.36
시가총액:
$691.11M
수익:
-
순이익/손실:
$-35.47M
주가수익비율:
-5.6514
EPS:
-0.57
순현금흐름:
$-124.27M
1주 성능:
-28.96%
1개월 성능:
+363.16%
6개월 성능:
+94.28%
1년 성능:
+47.26%
1일 변동 폭
$3.16
$3.56
1주일 범위
$3.15
$4.95
52주 변동 폭
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
명칭
Prokidney Corp
전화
336-999-7028
주소
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
PROK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
3.23 | 691.11M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.15 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
544.38 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.78 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
567.00 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.53 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 개시 | JP Morgan | Neutral |
| 2024-09-10 | 개시 | Guggenheim | Buy |
| 2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-07-25 | 개시 | BTIG Research | Buy |
| 2022-12-21 | 개시 | Jefferies | Buy |
| 2022-11-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 개시 | UBS | Buy |
| 2022-10-14 | 개시 | Citigroup | Buy |
| 2022-09-23 | 개시 | BofA Securities | Buy |
| 2022-09-02 | 개시 | Evercore ISI | Outperform |
모두보기
Prokidney Corp 주식(PROK)의 최신 뉴스
What drives ProKidney Corp. stock priceSuperior capital gains - Jammu Links News
What analysts say about ProKidney Corp. stockFree Predictions - Jammu Links News
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Best Momentum Stocks to Buy for July 17th - TradingView
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney gains pivotal therapy advancement step with FDA - Winston-Salem Journal
ProKidney completes Delaware domestication and restructures corporate agreements - Investing.com
Citi Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Will ProKidney’s Recent Surge Last? - StocksToTrade
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
ProKidney’s Strategic FDA Alignment and Promising Clinical Data Drive Buy Rating - TipRanks
ProKidney’s Hold Rating: Balancing FDA Alignment and Extended Approval Timeline - TipRanks
ProKidney price target raised to $7 from $6 at Guggenheim - MSN
ProKidney’s Dramatic Shares Tumble - timothysykes.com
Is ProKidney’s Slide a Buy Signal? - StocksToTrade
ProKidney Shares Plummet Amid Downgrades - timothysykes.com
UBS Initiates ProKidney(PROK.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial - MarketScreener
ProKidney Stock Skyrockets: What Does This Mean? - StocksToTrade
ProKidney, FDA align on accelerated approval pathway for Rilparencel - MSN
UBS Adjusts ProKidney Price Target to $8 From $4, Maintains Buy Rating - MarketScreener
ProKidney stock soars after FDA confirms accelerated approval pathway - Investing.com
Sector Update: Health Care - MarketScreener
ProKidney Soars 29.27% on FDA Milestone for CKD Therapy - AInvest
ProKidney Says FDA Confirms Accelerated Approval Pathway for Rilparencel - MarketScreener
Prokidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - MarketScreener
ProKidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - grafa.com
ProKidney Secures FDA Alignment for Rilparencel Approval - TipRanks
Why Did ProKidney Stock Plunge 5.15% Despite 169% YTD Surge? - AInvest
ProKidney stock price target raised to $8 from $4 at UBS on promising data By Investing.com - Investing.com South Africa
ProKidney stock price target raised to $8 from $4 at UBS on promising data - Investing.com India
ProKidney stock falls after FDA alignment on rilparencel approval pathway - Investing.com
ProKidney announces alignment with FDA on rilparencel accelerated approval path - TipRanks
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel - GlobeNewswire
ProKidney price target raised to $8 from $4 at UBS - TipRanks
ProKidney Enters New $200M Sale Agreement with Jefferies - TipRanks
ProKidney Plummets 26%—Is This the End of a Biotech Rally? - AInvest
ProKidney Faces Turbulence as Stock Plunges Amid Downgrades - StocksToTrade
ProKidney: Guggenheim maintains a 'Buy' Rating, The Target Price is $7 - AInvest
ProKidney's Innovative CKD Treatment Sparks Biotech InterestNews and Statistics - IndexBox
ProKidney stock price target raised to $7 from $6 at Guggenheim - Investing.com Australia
ProKidney stock price target raised to $7 from $6 at Guggenheim By Investing.com - Investing.com South Africa
ProKidney Just Set A New 52-Week High. Should You Buy, Sell, Or Hold PROK Stock Here? - Barchart.com
Promising clinical trial results give ProKidney share price major boost - Winston-Salem Journal
ProKidney spikes after mid-stage trial data for lead asset - MSN
The Globe’s stars and dogs for the week - The Globe and Mail
High-Potential Biotech Penny Stocks in 2025: ProKidney and Design Therapeutics Lead the Way - AInvest
ProKidney’s Investigation: A Game Changer? - timothysykes.com
ProKidney Stock (PROK): Is the Hype Justified? - Value The Markets
ProKidney Stock Soars 11.75% on Positive Phase 2 Study Results - AInvest
Prokidney Corp (PROK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.10%
자본화:
|
볼륨(24시간):